Abbvie Inc (NYSE: ABBV) has a higher price-to-earnings ratio of 59.83x compared to its average ratio. ABBV has 36-month beta value of 0.56. Analysts have mixed views on the stock, with 13 analysts rating it as a “buy,” 6 as “overweight,” 10 as “hold,” and 0 as “sell.”
The public float for ABBV is 1.77B, and currently, short sellers hold a 0.96% ratio of that float. The average trading volume of ABBV on January 20, 2025 was 6.36M shares.
ABBV) stock’s latest price update
Abbvie Inc (NYSE: ABBV) has seen a decline in its stock price by -1.23 in relation to its previous close of 173.70. However, the company has experienced a -2.06% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2025-01-19 that This article will reveal an in-depth analysis of drugs being developed to combat immunological disorders. Big Pharma is keenly interested in the global immunology drugs market, which is anticipated to exceed $190 billion by 2028. Every year, regulatory agencies approve dozens of biosimilars and brand-name drugs, so Seeking Alpha readers should be careful when making decisions.
ABBV’s Market Performance
Abbvie Inc (ABBV) has seen a -2.06% fall in stock performance for the week, with a -0.04% decline in the past month and a -9.92% plunge in the past quarter. The volatility ratio for the week is 2.13%, and the volatility levels for the past 30 days are at 1.93% for ABBV. The simple moving average for the last 20 days is -2.87% for ABBV stock, with a simple moving average of -3.96% for the last 200 days.
Analysts’ Opinion of ABBV
Many brokerage firms have already submitted their reports for ABBV stocks, with BofA Securities repeating the rating for ABBV by listing it as a “Neutral.” The predicted price for ABBV in the upcoming period, according to BofA Securities is $191 based on the research report published on December 10, 2024 of the previous year 2024.
Daiwa Securities, on the other hand, stated in their research note that they expect to see ABBV reach a price target of $180. The rating they have provided for ABBV stocks is “Neutral” according to the report published on December 05th, 2024.
Leerink Partners gave a rating of “Outperform” to ABBV, setting the target price at $206 in the report published on November 22nd of the previous year.
ABBV Trading at -3.31% from the 50-Day Moving Average
After a stumble in the market that brought ABBV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.25% of loss for the given period.
Volatility was left at 1.93%, however, over the last 30 days, the volatility rate increased by 2.13%, as shares sank -2.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.42% lower at present.
During the last 5 trading sessions, ABBV fell by -2.06%, which changed the moving average for the period of 200-days by -5.05% in comparison to the 20-day moving average, which settled at $176.62. In addition, Abbvie Inc saw -3.46% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABBV starting from Buckbee Kevin K, who sale 1,800 shares at the price of $172.24 back on Dec 16 ’24. After this action, Buckbee Kevin K now owns 6,983 shares of Abbvie Inc, valued at $310,032 using the latest closing price.
Buckbee Kevin K, the Officer of Abbvie Inc, proposed sale 1,800 shares at $172.25 during a trade that took place back on Dec 16 ’24, which means that Buckbee Kevin K is holding shares at $310,045 based on the most recent closing price.
Stock Fundamentals for ABBV
Current profitability levels for the company are sitting at:
- 0.25 for the present operating margin
- 0.77 for the gross margin
The net margin for Abbvie Inc stands at 0.09. The total capital return value is set at 0.14. Equity return is now at value 56.06, with 3.63 for asset returns.
Based on Abbvie Inc (ABBV), the company’s capital structure generated 0.92 points at debt to capital in total, while cash flow to debt ratio is standing at 0.23. The debt to equity ratio resting at 11.78. The interest coverage ratio of the stock is 5.44.
Currently, EBITDA for the company is 17.31 billion with net debt to EBITDA at 2.63. When we switch over and look at the enterprise to sales, we see a ratio of 6.61. The receivables turnover for the company is 4.84for trailing twelve months and the total asset turnover is 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.65.
Conclusion
To put it simply, Abbvie Inc (ABBV) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
